|
G |
Ache |
acetylcholinesterase |
increases activity multiple interactions |
EXP |
Galactosamine results in increased activity of ACHE protein Vitamin U inhibits the reaction [Galactosamine results in increased activity of ACHE protein] |
CTD |
PMID:35673974 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein] |
CTD |
PMID:27836788 PMID:27876602 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
increases expression |
EXP |
Galactosamine results in increased expression of ACTB mRNA |
CTD |
PMID:22563491 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
EXP |
Galactosamine results in increased expression of AFP protein |
CTD |
PMID:61145 PMID:16965562 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:37934488 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions decreases expression increases expression |
EXP |
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein] Galactosamine results in decreased expression of ALB protein Galactosamine results in increased expression of ALB mRNA |
CTD |
PMID:17963606 PMID:18779383 PMID:22310181 PMID:35838105 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
EXP |
Galactosamine results in increased expression of AMBP mRNA |
CTD |
PMID:18779383 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
Apoe |
apolipoprotein E |
decreases expression |
EXP |
Galactosamine results in decreased expression of APOE protein |
CTD |
PMID:6631239 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein |
CTD |
PMID:28844859 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of ATM protein glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein] |
CTD |
PMID:24565947 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form] Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA] |
CTD |
PMID:20558151 PMID:20850421 PMID:21401295 PMID:22118634 PMID:24565947 PMID:37934488 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein; [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form] glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein] Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein |
CTD |
PMID:20558151 PMID:20850421 PMID:22118634 PMID:24565947 PMID:37934488 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein |
CTD |
PMID:12907702 PMID:21401295 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] |
CTD |
PMID:32453893 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein] [Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein 2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein] |
CTD |
PMID:9388267 PMID:12907702 PMID:14512878 PMID:15486963 PMID:15565661 PMID:15610455 PMID:17602819 PMID:17936189 PMID:20558151 PMID:20850421 PMID:21146893 PMID:21401295 PMID:22023962 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:26176423 PMID:28887131 PMID:31332890 PMID:32453893 PMID:37934488 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein] |
CTD |
PMID:21146893 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein] |
CTD |
PMID:20558151 PMID:20850421 PMID:21146893 PMID:24830863 PMID:31332890 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
ISO EXP |
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein] mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein] |
CTD |
PMID:20558151 PMID:22118634 PMID:24830863 PMID:31332890 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases activity decreases activity |
ISO EXP |
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]] Galactosamine results in increased activity of CAT protein Galactosamine results in decreased activity of CAT protein [Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of CAT protein] |
CTD |
PMID:19153979 PMID:22154906 PMID:27836788 PMID:30236599 PMID:31022331 PMID:32453893 PMID:35673974 PMID:35691465 PMID:35838105 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]] |
CTD |
PMID:21146893 PMID:28887131 PMID:35691465 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein] |
CTD |
PMID:21146893 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein] |
CTD |
PMID:22107987 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] |
CTD |
PMID:20850421 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases phosphorylation multiple interactions |
EXP |
Galactosamine results in increased phosphorylation of CHUK protein mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein] |
CTD |
PMID:22310181 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of COL1A1 mRNA Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27876602 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions increases expression |
EXP |
Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA] |
CTD |
PMID:27876602 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
ISO |
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA] |
CTD |
PMID:17936189 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein |
CTD |
PMID:15576625 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein |
CTD |
PMID:15576625 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein] |
CTD |
PMID:28887131 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein] |
CTD |
PMID:20558151 PMID:20850421 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP |
Galactosamine results in decreased expression of CYP1A2 protein |
CTD |
PMID:16208626 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
EXP |
Galactosamine results in decreased expression of CYP2E1 protein [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein] |
CTD |
PMID:16208626 PMID:35838105 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression multiple interactions |
ISO |
Galactosamine results in decreased expression of CYP3A4 mRNA alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [alpha-Tocopherol results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:17936189 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA |
CTD |
PMID:28844859 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein] |
CTD |
PMID:36414212 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA |
CTD |
PMID:28844859 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein] |
CTD |
PMID:35838105 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA] |
CTD |
PMID:35691465 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA] |
CTD |
PMID:28887131 PMID:35691465 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf11 |
growth differentiation factor 11 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GDF11 protein; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein] |
CTD |
PMID:37934488 |
|
NCBI chr 7:1,311,732...1,325,211
Ensembl chr 7:1,311,732...1,320,725
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases expression |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein] (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein] |
CTD |
PMID:19153979 PMID:24565947 PMID:24830863 PMID:25620059 PMID:27876602 PMID:28844859 PMID:28887131 PMID:30236599 PMID:30822415 PMID:31332890 PMID:31445927 PMID:32453893 PMID:35838105 PMID:36414212 PMID:37934488 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
EXP |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of GSR protein] |
CTD |
PMID:35673974 PMID:35838105 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
H3f4 |
H3.4 histone, cluster member |
increases expression |
EXP |
Galactosamine results in increased expression of H3F4 mRNA |
CTD |
PMID:11779202 |
|
NCBI chr10:43,740,702...43,741,262
|
|
G |
Habp2 |
hyaluronan binding protein 2 |
increases activity |
ISO |
Galactosamine results in increased activity of HABP2 protein |
CTD |
PMID:11510480 |
|
NCBI chr 1:255,315,870...255,350,161
Ensembl chr 1:255,315,915...255,350,160
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA] |
CTD |
PMID:28887131 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein |
CTD |
PMID:28844859 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
ISO EXP |
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein; Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]] Galactosamine results in decreased expression of HMOX1 protein [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA] |
CTD |
PMID:14512878 PMID:19796704 PMID:21401295 PMID:22310181 PMID:35691465 PMID:35838105 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hp |
haptoglobin |
multiple interactions |
EXP |
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein] |
CTD |
PMID:36414212 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein |
CTD |
PMID:28844859 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO EXP |
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein] mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA] |
CTD |
PMID:15486963 PMID:22310181 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
EXP |
Galactosamine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:11779202 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions increases phosphorylation |
EXP |
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:22310181 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases expression |
ISO EXP |
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein] Galactosamine results in decreased expression of IL10 mRNA [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA] |
CTD |
PMID:15486963 PMID:17963606 PMID:22310181 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO EXP |
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA] |
CTD |
PMID:19913045 PMID:22310181 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il18 |
interleukin 18 |
increases expression multiple interactions |
ISO EXP |
Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA] [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein] |
CTD |
PMID:19913045 PMID:20102673 PMID:22310181 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
EXP ISO |
Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA] 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]] |
CTD |
PMID:15135310 PMID:22310181 PMID:25620059 PMID:28125915 PMID:28887131 PMID:30550845 PMID:32453893 PMID:35691465 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]] Galactosamine results in increased expression of IL6 mRNA [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein] |
CTD |
PMID:15135310 PMID:15486963 PMID:22310181 PMID:24830863 PMID:27836788 PMID:28887131 PMID:31332890 PMID:32453893 PMID:35691465 PMID:36414212 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein] |
CTD |
PMID:35691465 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
decreases activity |
EXP |
Galactosamine results in decreased activity of LCAT protein |
CTD |
PMID:6631239 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lep |
leptin |
multiple interactions increases response to substance |
ISO |
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine] |
CTD |
PMID:19913045 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions increases response to substance |
ISO |
[LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] |
CTD |
PMID:19913045 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form] Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form] Galactosamine results in increased phosphorylation of MAPK3 protein Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Maz |
MYC associated zinc finger protein |
multiple interactions |
EXP |
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein] |
CTD |
PMID:36414212 |
|
NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA |
CTD |
PMID:28844859 PMID:28887131 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mir34c |
microRNA 34c |
multiple interactions |
EXP |
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA] |
CTD |
PMID:36414212 |
|
NCBI chr 8:51,409,726...51,409,802
Ensembl chr 8:51,409,726...51,409,802
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO EXP |
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein] Galactosamine results in increased activity of MPO protein [Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]; Vitamin U inhibits the reaction [Galactosamine results in increased activity of MPO protein] |
CTD |
PMID:28887131 PMID:30550845 PMID:31022331 PMID:32453893 PMID:35673974 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein] |
CTD |
PMID:37934488 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
multiple interactions decreases expression |
ISO |
Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] |
CTD |
PMID:19523936 |
|
NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization increases activity multiple interactions decreases expression |
EXP ISO |
Galactosamine affects the localization of NFE2L2 protein Galactosamine results in increased activity of NFE2L2 protein [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein] mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein] |
CTD |
PMID:22310181 PMID:28887131 PMID:30114225 PMID:30203046 PMID:30236599 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:17936189 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases expression |
EXP ISO |
Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein] [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein] |
CTD |
PMID:15565661 PMID:20850421 PMID:22310181 PMID:28213090 PMID:30550845 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] |
CTD |
PMID:32453893 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein] Galactosamine results in increased expression of NOS2 mRNA alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA] Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA] |
CTD |
PMID:15189274 PMID:15565661 PMID:17936189 PMID:19796704 PMID:21401295 PMID:22107987 PMID:22118634 PMID:22310181 PMID:25620059 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
EXP ISO |
Galactosamine results in decreased expression of NQO1 protein 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein] mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein] |
CTD |
PMID:22310181 PMID:28887131 PMID:35691465 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein] |
CTD |
PMID:36414212 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:20558151 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein] |
CTD |
PMID:37934488 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions increases activity decreases expression |
ISO |
Galactosamine results in increased expression of PPARA mRNA [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein Galactosamine results in increased activity of PPARA protein alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA] |
CTD |
PMID:17936189 PMID:25689681 PMID:30203046 PMID:30236599 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein] |
CTD |
PMID:30236599 PMID:30550845 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppia |
peptidylprolyl isomerase A |
decreases expression |
EXP |
Galactosamine results in decreased expression of CYCA mRNA |
CTD |
PMID:22563491 |
|
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA] |
CTD |
PMID:22107987 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein] Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein] |
CTD |
PMID:22107987 PMID:25620059 PMID:32453893 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptn |
pleiotrophin |
increases expression |
EXP |
Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein |
CTD |
PMID:12057922 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
affects response to substance |
EXP |
PTTG1 mRNA affects the susceptibility to Galactosamine |
CTD |
PMID:19800905 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO EXP |
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein] alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein] |
CTD |
PMID:17936189 PMID:20850421 PMID:22310181 PMID:30550845 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sdc3 |
syndecan 3 |
increases expression |
EXP |
Galactosamine results in increased expression of SDC3 mRNA |
CTD |
PMID:12057922 |
|
NCBI chr 5:142,965,659...142,998,390
Ensembl chr 5:142,965,591...142,996,480
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Galactosamine results in increased expression of SERPINE1 mRNA |
CTD |
PMID:11779202 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein |
CTD |
PMID:25637945 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
EXP |
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:27876602 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions increases phosphorylation |
EXP |
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:27876602 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad7 |
SMAD family member 7 |
multiple interactions decreases expression |
EXP |
Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein] |
CTD |
PMID:27876602 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA |
CTD |
PMID:21401295 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein] |
CTD |
PMID:30822415 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] |
CTD |
PMID:19913045 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:28887131 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
decreases activity |
ISO |
Galactosamine results in decreased activity of STAT5B protein |
CTD |
PMID:30114225 |
|
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein] |
CTD |
PMID:27836788 PMID:27876602 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein] |
CTD |
PMID:36414212 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] |
CTD |
PMID:28125915 PMID:32453893 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]] Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein [Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein] |
CTD |
PMID:9388267 PMID:10221824 PMID:11779202 PMID:14512878 PMID:15135310 PMID:15486963 PMID:16431966 PMID:17602819 PMID:17963606 PMID:20054000 PMID:20558151 PMID:22107987 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:25620059 PMID:26176423 PMID:27836788 PMID:28125915 PMID:28213090 PMID:28887131 PMID:30550845 PMID:30822415 PMID:31332890 PMID:32453893 PMID:35691465 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA |
CTD |
PMID:28844859 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xdh |
xanthine dehydrogenase |
increases activity multiple interactions |
EXP |
Galactosamine results in increased activity of XDH protein Vitamin U inhibits the reaction [Galactosamine results in increased activity of XDH protein] |
CTD |
PMID:35673974 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] |
CTD |
PMID:20850421 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Glucosamine results in increased expression of AACS mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Glucosamine results in increased expression of ACACA mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression decreases expression affects expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein Glucosamine results in increased expression of ACAN mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA] Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein Glucosamine analog results in decreased expression of ACAN mRNA Glucosamine analog affects the expression of ACAN mRNA |
CTD |
PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 PMID:18321735 PMID:19909832 More...
|
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ACSS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
multiple interactions decreases expression |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression multiple interactions |
ISO EXP |
Glucosamine analog results in decreased expression of ADAMTS1 mRNA Glucosamine results in decreased expression of ADAMTS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA] |
CTD |
PMID:16300972 PMID:17109745 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
increases expression |
EXP |
Glucosamine results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS5 mRNA Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form |
CTD |
PMID:16300972 PMID:19909832 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO EXP |
Glucosamine results in increased expression of ADIPOQ mRNA |
CTD |
PMID:15694357 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Glucosamine results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
increases expression |
ISO |
Glucosamine results in increased expression of AGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of AHI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation multiple interactions |
ISO |
Glucosamine analog affects the phosphorylation of AKT1 protein Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]] Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18080321 PMID:18340449 PMID:30602124 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression increases activity |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein] Glucosamine analog results in increased expression of ALPL mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases secretion increases stability |
ISO |
Glucosamine results in increased secretion of APOA1 protein Glucosamine results in increased stability of APOA1 mRNA |
CTD |
PMID:15164326 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases degradation increases ubiquitination decreases secretion decreases localization decreases expression |
ISO EXP |
acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] Glucosamine results in increased ubiquitination of APOB protein Glucosamine results in decreased localization of APOB protein Glucosamine results in decreased expression of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] |
CTD |
PMID:16380481 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA] Glucosamine results in increased expression of ATF6 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in decreased expression of ATF6 mRNA |
CTD |
PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
increases expression |
ISO |
Glucosamine results in increased expression of ATF7IP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of AZIN1 mRNA IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
multiple interactions increases expression |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA] |
CTD |
PMID:11229466 PMID:11801247 |
|
NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BCL2L1 protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
Glucosamine results in decreased expression of BDNF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Glucosamine analog results in increased expression of BGLAP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bgn |
biglycan |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein |
CTD |
PMID:24442997 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of BMP4 mRNA Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA] Glucosamine results in decreased expression of BMP6 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA] Glucosamine results in increased expression of BMP7 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Glucosamine results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CAR3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of CASP3 protein Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:16850161 PMID:22020377 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CASP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cbr2 |
carbonyl reductase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:106,008,535...106,012,838
Ensembl chr10:105,991,589...106,013,001
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein] Glucosamine results in increased expression of CCL2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein] Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA] |
CTD |
PMID:17109745 PMID:18080321 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP |
Glucosamine analog results in increased expression of CCN2 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
Glucosamine results in increased expression of CD24A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd28 |
Cd28 molecule |
increases expression |
EXP |
Glucosamine results in increased expression of CD28 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC20 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc23 |
cell division cycle 23 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC23 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP ISO |
Glucosamine results in increased expression of CDKN1A protein Glucosamine results in increased expression of CDKN1A mRNA |
CTD |
PMID:15654767 PMID:17178593 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN1B protein |
CTD |
PMID:15654767 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
EXP |
Glucosamine results in decreased expression of CENPF mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:16142878 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions decreases activity |
ISO |
Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein Glucosamine analog results in decreased activity of CHUK protein |
CTD |
PMID:20113495 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein |
CTD |
PMID:24442997 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Clta |
clathrin, light chain A |
decreases expression |
EXP |
Glucosamine results in decreased expression of CLTA mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA] Glucosamine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions affects expression increases expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA] Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA] Glucosamine analog affects the expression of COL2A1 mRNA Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA |
CTD |
PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA] Glucosamine results in increased expression of CSF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA] Glucosamine results in increased expression of CSF3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases activity decreases expression |
ISO |
Glucosamine affects the localization of CTSD protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] Glucosamine results in increased activity of CTSD protein |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO EXP |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA] |
CTD |
PMID:17109745 PMID:20737476 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions decreases expression |
EXP |
Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Glucosamine results in decreased expression of CYBA mRNA |
CTD |
PMID:18077487 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Glucosamine affects the localization of CYCS protein |
CTD |
PMID:15972124 PMID:22020377 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Glucosamine results in increased expression of CYP51 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
ISO |
Glucosamine results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO |
Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein] Glucosamine results in decreased expression of DDIT3 mRNA |
CTD |
PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
EXP |
Glucosamine results in increased expression of DDIT4L mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
Glucosamine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of DSPP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA] Glucosamine results in increased expression of DUSP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased expression of EIF2AK3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein] EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucosamine results in increased phosphorylation of EIF2S1 protein NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Glucosamine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of EPAS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EPRS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
ISO |
ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of FABP4 mRNA |
CTD |
PMID:15694357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Glucosamine results in increased expression of FASN mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of FBP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of FGF7 mRNA IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA] Glucosamine results in increased expression of FGF9 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA] Glucosamine results in increased expression of FGFR1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of FKBP11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO EXP |
Glucosamine results in decreased expression of FN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] |
CTD |
PMID:19375915 PMID:21825963 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases cleavage multiple interactions |
ISO |
Glucosamine results in decreased cleavage of FURIN protein alternative form Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein |
CTD |
PMID:19909832 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Glucosamine results in increased expression of FXYD2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gatm |
glycine amidinotransferase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GATM mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GCK mRNA |
CTD |
PMID:11893929 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Glucosamine analog results in increased expression of GCLC mRNA |
CTD |
PMID:21825963 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
EXP |
[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein |
CTD |
PMID:9453242 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
Glucosamine results in increased expression of GLRX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of GNPNAT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739
|
|
G |
Gnptab |
N-acetylglucosamine-1-phosphate transferase subunits alpha and beta |
increases expression |
ISO |
Glucosamine results in increased expression of GNPTAB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:22,800,502...22,866,336
Ensembl chr 7:22,800,485...22,866,933
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1 like |
increases expression |
ISO |
Glucosamine results in increased expression of GPD1L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases phosphorylation |
ISO |
Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] Glucosamine results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:33812996 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GSTT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of HAPLN1 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein |
CTD |
PMID:19254699 PMID:22020377 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of HK1 mRNA |
CTD |
PMID:11893929 PMID:17178593 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
EXP |
Glucosamine results in increased expression of HMGA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
EXP |
Glucosamine results in decreased expression of HMMR mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein] Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein |
CTD |
PMID:18077487 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HOXA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases expression |
EXP |
Glucosamine results in decreased expression of HPGD mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
ISO EXP |
Glucosamine results in decreased expression of HSP90B1 mRNA Glucosamine results in increased expression of HSP90B1 protein |
CTD |
PMID:15618547 PMID:17109745 PMID:17178593 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in increased expression of HSPA5 mRNA; Glucosamine results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:15618547 PMID:16380481 PMID:17178593 PMID:19383982 PMID:20165829 PMID:22020377 PMID:30602124 PMID:33812996 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HYOU1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases activity |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein] Glucosamine results in decreased activity of ICAM1 protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 PMID:16822504 PMID:17238806 PMID:18949387 PMID:19020780 PMID:19098112 More...
|
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ID1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ID2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
Glucosamine results in increased expression of ID3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases expression |
ISO |
Glucosamine results in increased expression of IDH1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
Glucosamine results in increased expression of IFIT3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifng |
interferon gamma |
decreases secretion multiple interactions |
ISO |
Glucosamine results in decreased secretion of IFNG protein Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]] |
CTD |
PMID:14507305 PMID:16431966 PMID:16822504 PMID:17238806 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA] Glucosamine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] Glucosamine results in increased expression of IGFBP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein] |
CTD |
PMID:18786831 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA] Glucosamine results in decreased expression of IL13RA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681 Ensembl chr11:115,348,860...115,408,681
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitrites]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] Glucosamine results in increased expression of IL1B mRNA Glucosamine results in decreased expression of IL1B mRNA [IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA; Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:11229466 PMID:11801247 PMID:12681956 PMID:15144122 PMID:16822504 PMID:17109745 PMID:17238806 PMID:17337215 PMID:17605605 PMID:17925024 PMID:18026701 PMID:18077487 PMID:18080321 PMID:18321735 PMID:18340449 PMID:18786831 PMID:19626664 PMID:19656660 PMID:20737476 PMID:21219853 PMID:22089456 PMID:38437956 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
multiple interactions |
EXP |
[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA |
CTD |
PMID:11801247 |
|
NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
ISO |
Glucosamine results in decreased secretion of IL2 protein |
CTD |
PMID:14507305 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23r |
interleukin 23 receptor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021
|
|
G |
Il33 |
interleukin 33 |
decreases expression |
EXP |
Glucosamine results in decreased expression of IL33 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL4 protein Glucosamine results in decreased expression of IL4 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL5 protein Glucosamine results in decreased expression of IL5 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Glucosamine analog results in decreased expression of IL6 mRNA; Glucosamine results in decreased expression of IL6 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:16822504 PMID:17109745 PMID:18786831 PMID:19098112 PMID:20093129 PMID:20113495 PMID:20307528 PMID:20737476 PMID:38437956 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5k |
inositol polyphosphate-5-phosphatase K |
multiple interactions increases expression |
ISO |
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA] |
CTD |
PMID:33812996 |
|
NCBI chr10:60,474,262...60,495,813
Ensembl chr10:60,475,897...60,496,773
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; [Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:9453242 PMID:11893929 PMID:16380481 PMID:20165829 PMID:30602124 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 PMID:33812996 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IRF1 mRNA] |
CTD |
PMID:20737476 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ISYNA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases expression |
EXP ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA] [Glucosamine co-treated with Lipopolysaccharides] results in increased phosphorylation of JAK2 protein |
CTD |
PMID:17109745 PMID:38437956 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein] Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] |
CTD |
PMID:17925024 PMID:21825963 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein] |
CTD |
PMID:17925024 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
ISO |
Glucosamine results in increased expression of KCNJ16 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:95,990,009...96,021,356
Ensembl chr10:95,960,725...96,021,702
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF11 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif4a |
kinesin family member 4A |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF4A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Klf10 |
KLF transcription factor 10 |
increases expression |
ISO |
Glucosamine results in increased expression of KLF10 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Lama4 |
laminin subunit alpha 4 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of LCN2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lepr |
leptin receptor |
affects response to substance multiple interactions |
EXP |
LEPR protein affects the susceptibility to Glucosamine [LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of LPIN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
ISO |
Glucosamine results in increased expression of LY6A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981
|
|
G |
Mafb |
MAF bZIP transcription factor B |
increases expression |
EXP |
Glucosamine results in increased expression of MAFB mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Glucosamine analog results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:19626664 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Glucosamine analog results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Glucosamine analog results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:18080321 PMID:19626664 PMID:20307528 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Glucosamine results in decreased expression of MCL1 mRNA; Glucosamine results in decreased expression of MCL1 protein |
CTD |
PMID:22020377 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] Glucosamine results in decreased expression of MEF2A mRNA; Glucosamine results in decreased expression of MEF2A protein |
CTD |
PMID:20165829 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mettl1 |
methyltransferase 1, tRNA methylguanosine |
decreases expression |
ISO |
Glucosamine results in decreased expression of METTL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:62,864,860...62,869,202
Ensembl chr 7:62,864,853...62,869,202
|
|
G |
Mfap3l |
microfibril associated protein 3 like |
increases expression |
ISO |
Glucosamine results in increased expression of MFAP3L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Glucosamine results in decreased expression of MKI67 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:15144122 PMID:17925024 PMID:18080321 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of MMP10 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
affects expression multiple interactions increases expression |
ISO EXP |
Glucosamine analog affects the expression of MMP13 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA] Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:15144122 PMID:17109745 PMID:17337215 PMID:17925024 PMID:18080321 PMID:19656660 More...
|
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP2 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 protein] IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine results in decreased expression of and results in decreased activity of MMP3 protein Glucosamine results in increased expression of MMP3 mRNA Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA] Glucosamine analog results in decreased expression of MMP3 mRNA |
CTD |
PMID:11229466 PMID:12801482 PMID:15144122 PMID:16300972 PMID:17109745 PMID:17925024 PMID:18080321 PMID:18340449 PMID:20110869 More...
|
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein] Glucosamine results in increased expression of MMP9 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
increases expression |
ISO |
Glucosamine results in increased expression of IFI204 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
EXP |
Glucosamine results in decreased activity of MPO protein |
CTD |
PMID:19098112 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
ISO |
Glucosamine results in increased expression of MVD mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
increases expression |
EXP |
Glucosamine results in increased expression of NDUFA4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
EXP |
Glucosamine results in decreased expression of NEDD4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases activity |
ISO EXP |
Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NFKB1 protein] Glucosamine results in decreased activity of NFKB1 protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein] |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17498959 PMID:18036590 PMID:18205790 PMID:20737476 More...
|
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] Glucosamine results in decreased phosphorylation of NFKBIA protein Glucosamine results in decreased expression of NFKBIA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA protein modified form]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:12681956 PMID:17109745 PMID:18080321 PMID:18205790 PMID:19098112 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
increases expression |
ISO |
Glucosamine results in increased expression of NGEF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] Glucosamine results in increased expression of NOS2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA] Glucosamine results in decreased expression of NOS2 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109745 PMID:17440993 PMID:17605605 PMID:18077487 PMID:18205790 PMID:19098112 PMID:20737476 PMID:38437956 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects expression |
EXP |
Glucosamine affects the expression of NR1H4 |
CTD |
PMID:19373748 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
ISO |
Glucosamine results in increased expression of NSDHL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of NUCB2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
decreases expression |
EXP |
Glucosamine results in decreased expression of NUF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Nus1 |
NUS1 dehydrodolichyl diphosphate synthase subunit |
multiple interactions |
ISO |
NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr20:31,811,817...31,838,562
Ensembl chr20:31,811,817...31,838,561
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of OGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Orc2 |
origin recognition complex, subunit 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ORC2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:60,001,631...60,038,301
Ensembl chr 9:60,001,910...60,038,195
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA] |
CTD |
PMID:21219853 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Ostn |
osteocrin |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of OSTN mRNA 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:30602124 |
|
NCBI chr11:73,442,167...73,478,498
Ensembl chr11:73,442,487...73,468,603
|
|
G |
Oxr1 |
oxidation resistance 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of OXR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:72,528,750...72,965,666
Ensembl chr 7:72,528,786...72,965,666
|
|
G |
Pank1 |
pantothenate kinase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of PANK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:232,328,430...232,396,829
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of PARP1 protein pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:16850161 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PDGFA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of PDK4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
Glucosamine results in increased expression of PFKP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PIGA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PLA2G4A mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
Glucosamine results in increased expression of PLAT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plk1 |
polo-like kinase 1 |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of PLK1 mRNA Glucosamine results in decreased expression of PLK1 mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PLPP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
Glucosamine promotes the reaction [IL1B results in increased expression of PPARG] Glucosamine results in increased expression of PPARG mRNA |
CTD |
PMID:15694357 PMID:22089456 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] Glucosamine results in decreased expression of PPARGC1A mRNA; Glucosamine results in decreased expression of PPARGC1A protein |
CTD |
PMID:20165829 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPM1A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Psme3 |
proteasome activator subunit 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PSME3 |
CTD |
PMID:21697645 |
|
NCBI chr10:86,257,672...86,265,458
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA] |
CTD |
PMID:17605605 PMID:22089456 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression decreases expression multiple interactions decreases glycosylation |
ISO EXP |
Glucosamine analog results in increased expression of PTGS2 protein alternative form Glucosamine results in decreased expression of PTGS2 mRNA Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] Glucosamine results in decreased glycosylation of PTGS2 protein [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:12681956 PMID:17440993 PMID:17605605 PMID:18205790 PMID:19656660 PMID:20737476 PMID:22089456 PMID:38437956 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
decreases expression |
EXP |
Glucosamine results in decreased expression of PTTG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
increases expression |
ISO |
Glucosamine results in increased expression of RAB32 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
decreases expression |
ISO |
Glucosamine results in decreased expression of RBM39 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Recql4 |
RecQ like helicase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of RECQL4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity increases localization |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] Glucosamine results in decreased activity of RELA protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] Glucosamine results in increased localization of RELA protein |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17238806 PMID:17498959 PMID:18036590 PMID:18080321 PMID:18205790 PMID:18340449 PMID:18786831 PMID:19020780 PMID:19375915 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
ISO |
Glucosamine results in increased expression of RHOB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of RHOC mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rnd1 |
Rho family GTPase 1 |
multiple interactions decreases expression |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA] Glucosamine results in decreased expression of RND1 mRNA |
CTD |
PMID:17178593 PMID:18173918 |
|
NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19254699 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:19254699 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Glucosamine analog results in increased phosphorylation of RUNX2 protein Glucosamine analog results in increased expression of RUNX2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SCD2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SERPINB2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINH1 protein |
CTD |
PMID:16380481 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SFRP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SGK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Shcbp1 |
SHC binding and spindle associated 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SHCBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC17A1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC23A2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions decreases expression increases uptake |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] Glucosamine results in decreased expression of SLC2A4 mRNA; Glucosamine results in decreased expression of SLC2A4 protein SLC2A4 protein results in increased uptake of Glucosamine Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine] |
CTD |
PMID:19373748 PMID:20165829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC2A6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc37a4 |
solute carrier family 37 member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC37A4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301
|
|
G |
Slc4a4 |
solute carrier family 4 member 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC4A4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883
|
|
G |
Slc7a8 |
solute carrier family 7 member 8 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of SLC7A8 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SMPD3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA] Glucosamine results in decreased expression of SOX4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Srsf3 |
serine and arginine rich splicing factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SRSF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
|
|
G |
St6gal1 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ST6GAL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein] |
CTD |
PMID:16431966 PMID:17238806 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TACC3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Testin |
testin gene |
decreases expression |
EXP |
Glucosamine results in decreased expression of TESTIN mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
EXP |
[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Glucosamine analog results in increased expression of TGFB1 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
increases expression multiple interactions |
ISO |
Glucosamine analog results in increased expression of TGFBR1 protein 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased expression of TGFBR1 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Thbs4 |
thrombospondin 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of TIMP2 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions increases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA Glucosamine results in increased expression of TIMP3 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA] |
CTD |
PMID:17109745 PMID:17605605 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tinag |
tubulointerstitial nephritis antigen |
increases expression |
ISO |
Glucosamine results in increased expression of TINAG mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:77,800,031...77,885,077
Ensembl chr 8:77,800,032...77,885,077
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Glucosamine results in increased expression of TLR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
ISO EXP |
Glucosamine results in decreased secretion of TNF protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Glucosamine analog results in decreased expression of TNF mRNA; Glucosamine results in decreased expression of TNF mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF; Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:14507305 PMID:16431966 PMID:16445576 PMID:16822504 PMID:17238806 PMID:18173918 PMID:18205790 PMID:18786831 PMID:19020780 PMID:19098112 PMID:20093129 PMID:20110869 PMID:20113495 PMID:20737476 PMID:38437956 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:17996099 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnk2 |
tyrosine kinase, non-receptor, 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:68,114,725...68,154,254
Ensembl chr11:68,114,726...68,154,009
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression |
EXP |
Glucosamine results in decreased expression of TOP2A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of TRPV4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
EXP ISO |
Glucosamine results in decreased expression of TXN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression multiple interactions |
EXP ISO |
Glucosamine results in increased expression of TXNIP protein Glucosamine results in increased expression of TXNIP mRNA; Glucosamine results in increased expression of TXNIP protein Glucosamine promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of UCP2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
increases expression |
ISO |
Glucosamine results in increased expression of UQCRH mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242
|
|
G |
Vamp1 |
vesicle-associated membrane protein 1 |
increases expression |
EXP |
Glucosamine results in increased expression of VAMP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:158,012,634...158,019,350
Ensembl chr 4:158,012,663...158,019,349
|
|
G |
Vcan |
versican |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression decreases expression |
ISO EXP |
Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] Glucosamine results in increased expression of VEGFA protein Glucosamine results in decreased expression of VEGFA protein |
CTD |
PMID:16324875 PMID:19254699 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of VEGFD mRNA Glucosamine results in decreased expression of VEGFD mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vnn1 |
vanin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of VNN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions increases splicing increases expression decreases splicing |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] 4-methylumbelliferone 8-carbaldehyde affects the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in decreased splicing of XBP1 mRNA |
CTD |
PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Zfp467 |
zinc finger protein 467 |
increases expression |
ISO |
Glucosamine results in increased expression of ZFP467 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229
|
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of CEBPA protein |
CTD |
PMID:19427183 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of DLK1 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FABP4 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FAS mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LEP mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
glucosamine 6-phosphate results in increased expression of LIPE mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LPL mRNA |
CTD |
PMID:19427183 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of PPARG protein |
CTD |
PMID:19427183 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of SREBF1 protein |
CTD |
PMID:19427183 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of TNF mRNA |
CTD |
PMID:19427183 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cmas |
cytidine monophosphate N-acetylneuraminic acid synthetase |
affects abundance |
ISO |
CMAS protein affects the abundance of N-Acetylneuraminic Acid; CMAS protein affects the abundance of N-Acetylneuraminic Acid analog |
CTD |
PMID:27380425 |
|
NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125
|
|
G |
Gne |
glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase |
increases chemical synthesis |
EXP |
GNE protein results in increased chemical synthesis of N-Acetylneuraminic Acid |
CTD |
PMID:9305888 |
|
NCBI chr 5:58,267,189...58,307,396
Ensembl chr 5:58,267,210...58,307,499
|
|
G |
Nans |
N-acetylneuraminate synthase |
increases chemical synthesis |
ISO |
NANS results in increased chemical synthesis of N-Acetylneuraminic Acid |
CTD |
PMID:27213289 |
|
NCBI chr 5:60,780,441...60,797,583
Ensembl chr 5:60,780,392...60,814,950
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Glucosamine results in increased expression of AACS mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Glucosamine results in increased expression of ACACA mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression decreases expression affects expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein Glucosamine results in increased expression of ACAN mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA] Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein Glucosamine analog results in decreased expression of ACAN mRNA Glucosamine analog affects the expression of ACAN mRNA |
CTD |
PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 PMID:18321735 PMID:19909832 More...
|
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ACSS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
multiple interactions decreases expression |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression multiple interactions |
ISO EXP |
Glucosamine analog results in decreased expression of ADAMTS1 mRNA Glucosamine results in decreased expression of ADAMTS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA] |
CTD |
PMID:16300972 PMID:17109745 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
increases expression |
EXP |
Glucosamine results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS5 mRNA Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form |
CTD |
PMID:16300972 PMID:19909832 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO EXP |
Glucosamine results in increased expression of ADIPOQ mRNA |
CTD |
PMID:15694357 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Glucosamine results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
increases expression |
ISO |
Glucosamine results in increased expression of AGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of AHI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation multiple interactions |
ISO |
Glucosamine analog affects the phosphorylation of AKT1 protein Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]] Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18080321 PMID:18340449 PMID:30602124 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression increases activity |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein] Glucosamine analog results in increased expression of ALPL mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases secretion increases stability |
ISO |
Glucosamine results in increased secretion of APOA1 protein Glucosamine results in increased stability of APOA1 mRNA |
CTD |
PMID:15164326 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases degradation increases ubiquitination decreases secretion decreases localization decreases expression |
ISO EXP |
acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] Glucosamine results in increased ubiquitination of APOB protein Glucosamine results in decreased localization of APOB protein Glucosamine results in decreased expression of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] |
CTD |
PMID:16380481 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in increased expression of ATF6 protein ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in decreased expression of ATF6 mRNA |
CTD |
PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
increases expression |
ISO |
Glucosamine results in increased expression of ATF7IP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of AZIN1 mRNA IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
multiple interactions increases expression |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA] |
CTD |
PMID:11229466 PMID:11801247 |
|
NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BCL2L1 protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
Glucosamine results in decreased expression of BDNF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Glucosamine analog results in increased expression of BGLAP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bgn |
biglycan |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein |
CTD |
PMID:24442997 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of BMP4 mRNA Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA] Glucosamine results in decreased expression of BMP6 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA] Glucosamine results in increased expression of BMP7 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Glucosamine results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CAR3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of CASP3 protein Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:16850161 PMID:22020377 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CASP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cbr2 |
carbonyl reductase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:106,008,535...106,012,838
Ensembl chr10:105,991,589...106,013,001
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein] Glucosamine results in increased expression of CCL2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein] Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA] |
CTD |
PMID:17109745 PMID:18080321 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP |
Glucosamine analog results in increased expression of CCN2 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
Glucosamine results in increased expression of CD24A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd28 |
Cd28 molecule |
increases expression |
EXP |
Glucosamine results in increased expression of CD28 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC20 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc23 |
cell division cycle 23 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC23 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP ISO |
Glucosamine results in increased expression of CDKN1A protein Glucosamine results in increased expression of CDKN1A mRNA |
CTD |
PMID:15654767 PMID:17178593 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN1B protein |
CTD |
PMID:15654767 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
EXP |
Glucosamine results in decreased expression of CENPF mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:16142878 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions decreases activity |
ISO |
Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein Glucosamine analog results in decreased activity of CHUK protein |
CTD |
PMID:20113495 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein |
CTD |
PMID:24442997 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Clta |
clathrin, light chain A |
decreases expression |
EXP |
Glucosamine results in decreased expression of CLTA mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA] Glucosamine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions affects expression increases expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA] Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA] Glucosamine analog affects the expression of COL2A1 mRNA Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA |
CTD |
PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA] Glucosamine results in increased expression of CSF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA] Glucosamine results in increased expression of CSF3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases activity decreases expression |
ISO |
Glucosamine affects the localization of CTSD protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] Glucosamine results in increased activity of CTSD protein |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO EXP |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA] |
CTD |
PMID:17109745 PMID:20737476 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions decreases expression |
EXP |
Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Glucosamine results in decreased expression of CYBA mRNA |
CTD |
PMID:18077487 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Glucosamine affects the localization of CYCS protein |
CTD |
PMID:15972124 PMID:22020377 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Glucosamine results in increased expression of CYP51 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
ISO |
Glucosamine results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO |
Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein] Glucosamine results in decreased expression of DDIT3 mRNA |
CTD |
PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
EXP |
Glucosamine results in increased expression of DDIT4L mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
Glucosamine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of DSPP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA] Glucosamine results in increased expression of DUSP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased expression of EIF2AK3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein] EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucosamine results in increased phosphorylation of EIF2S1 protein NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Glucosamine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of EPAS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EPRS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
ISO |
ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] Glucosamine results in increased expression of ERN1 mRNA NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of FABP4 mRNA |
CTD |
PMID:15694357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Glucosamine results in increased expression of FASN mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of FBP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of FGF7 mRNA IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA] Glucosamine results in increased expression of FGF9 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA] Glucosamine results in increased expression of FGFR1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of FKBP11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO EXP |
Glucosamine results in decreased expression of FN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] |
CTD |
PMID:19375915 PMID:21825963 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases cleavage multiple interactions |
ISO |
Glucosamine results in decreased cleavage of FURIN protein alternative form Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein |
CTD |
PMID:19909832 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Glucosamine results in increased expression of FXYD2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gatm |
glycine amidinotransferase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GATM mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GCK mRNA |
CTD |
PMID:11893929 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Glucosamine analog results in increased expression of GCLC mRNA |
CTD |
PMID:21825963 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
EXP |
[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein |
CTD |
PMID:9453242 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
Glucosamine results in increased expression of GLRX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of GNPNAT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739
|
|
G |
Gnptab |
N-acetylglucosamine-1-phosphate transferase subunits alpha and beta |
increases expression |
ISO |
Glucosamine results in increased expression of GNPTAB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:22,800,502...22,866,336
Ensembl chr 7:22,800,485...22,866,933
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1 like |
increases expression |
ISO |
Glucosamine results in increased expression of GPD1L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation multiple interactions |
ISO |
Glucosamine results in decreased phosphorylation of GSK3B protein Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GSTT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of HAPLN1 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein |
CTD |
PMID:19254699 PMID:22020377 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of HK1 mRNA |
CTD |
PMID:11893929 PMID:17178593 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
EXP |
Glucosamine results in increased expression of HMGA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
EXP |
Glucosamine results in decreased expression of HMMR mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein] Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein |
CTD |
PMID:18077487 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HOXA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases expression |
EXP |
Glucosamine results in decreased expression of HPGD mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
|